Proliferation and activation of microglial cells is a neuropathological characteristic of brain injury and neurodegeneration, including Alzheimer's disease. Microglia act as the first and main form of immune defense in the nervous system. While the primary function of microglia is to survey and maintain the cellular environment optimal for neurons in the brain parenchyma by actively scavenging the brain for damaged brain cells and foreign proteins or particles, sustained activation of microglia may result in high production of proinflammatory mediators that disturb normal brain functions and even cause neuronal injury. Glycogen synthase kinase-3β has been recently identified as a major regulator of immune system and mediates inflammatory responses in microglia. Glycogen synthase kinase-3β has been extensively investigated in connection to tau and amyloid β toxicity, whereas reports on the role of this enzyme in neuroinflammation in Alzheimer's disease are negligible. Here we review and discuss the role of glycogen synthase-3β in immune cells in the context of Alzheimer's disease pathology.
1. Inflammation in Alzheimer’s Disease
In addition to progressive loss of neurons and accumulation of intra- and extracellular protein deposits, chronic inflammation is a major pathological hallmark of Alzheimer’s disease (AD) [1, 2]. Neuroinflammation in AD is characterized by the existence of inflammatory mediator cells surrounding the β-amyloid (Aβ) plaques and sites of neuronal injury [3–5]. Even though microglia, the main immune cells of the brain, have been extensively studied in AD, the exact role of inflammation in the disease pathogenesis remains elusive [3–10]. There is substantial evidence that microglia and the monocytic cells derived from the blood or bone marrow at least initially protect neurons from neurotoxic accumulation of Aβ and even release neurotrophic factors and extracellular proteases which may support neuronal survival and regeneration [5–11]. On the other hand, extensive and long-term release of proinflammatory mediators and reactive oxygen or nitrogen species (ROS and RNS) by the inflammatory cells is thought to accelerate neurodegeneration and disturb cognitive functions [3–10].
The primary inflammatory cells in the central nervous system are microglia, constituting around 10% of all cells in the brain. They represent the innate immune system and form the first line of defense against invading pathogens in the brain [12–14]. Microglia serve as sensors for disturbed brain tissue homeostasis as they accumulate and proliferate locally in response to neuronal injury or penetration of foreign material in the brain [13, 14]. In AD, such activation can result from extracellular deposition of Aβ, neuronal injury caused by Aβ or tau toxicity [5–15], to some extent from ischemic or traumatic brain injury, and may be contributed even by local or systemic infection [16, 17]. In addition to microglia, astrocytes, pericytes, endothelial cells and neurons are thought to play a role in inflammatory responses relevant to AD [18]. However, most of the data on the impact of inflammation in AD originate from studies with microglia.
2. Glycogen Synthase Kinase 3-β in the Nervous System
Glycogen synthase kinase 3 (GSK-3) is a multifunctional serine/threonine kinase present in all eukaryotes. There are two highly homologous isoforms of GSK-3, GSK-3α and GSK-3β, that are usually equivalent in actions. In addition, there is an alternatively spliced GSK-3β variant that encodes GSK-3β2, which has a 13-residue insert in the kinase domain [19–25] and is expressed exclusively in the nervous system [19–25]. GSK-3 shows partial constitutive activity and is known to phosphorylate more than 50 different substrates. The most important mechanism for regulation of GSK-3β activity is inhibitory phosphorylation of Ser9 by protein kinase A (PKA) protein kinase B (PKB)/Akt and protein kinase C (KPC). Other kinases may phosphorylate the regulatory Ser9 as well. Activation of GSK-3β is enhanced when also the regulatory Tyr216 is phosphorylated [19–25].
In the brain, GSK-3β is known to be involved in neurogenesis, neuronal migration, neuronal polarization, and axon growth and guidance. GSK3β2 shows the highest expression in the nervous system during development and seems to have a special role in neuronal morphogenesis [25–32]. GSK-3β affects axon growth by controlling microtubule dynamics through phosphorylation of microtubule-associated proteins (MAPs) such as Tau, MAP-1B and adenomatous polyposis coli [25–32]. Importantly, GSK-3β plays a key role in neuropathology of AD, schizophrenia, autism and Parkinson’s disease (PD). Also, the polymorphisms in GSK3β interact with the microtubule-associated protein Tau (MAPT) haplotypes to increase the risk for idiopathic PD and AD [32–35].
There is substantial evidence that activation of GSK-3β contributes to tau pathology, Aβ synthesis, and apoptotic neuronal death and it is thus not surprising that GSK-3β has been recognized as a potential therapeutic target in AD [35–37]. However, GSK-3β is a well-known regulator of innate and adaptive immune responses and plays a key role also in pathways of microglial activation relevant to AD [19, 20, 38–41]. Considering that neuroinflammation is a characteristic of AD brain pathology, the role of GSK-3β in glial cells is of great interest. The therapeutically interesting role of GSK-3β in regulating inflammation in AD is emphasized by the fact that various forms of Aβ promote microglial activation and release of proinflammatory mediators and ROS/RNS. In addition, in vitro studies suggest that microglial activation may in turn induce accumulation of tau in neurites though microglial ROS production [15].
3. GSK-3β and Migration of Microglia
Migration of blood and bone marrow-derived monocytic cells as well as endogenous microglia to the sites of brain injury and abnormal proteins, such as Aβ, is a necessary step before production of proinflammatory mediators or neurotoxins and attempts of phagocytosis [10, 11, 13, 42–48]. GSK-3β has been reported to be a key kinase regulating migration of various cell types, such as different stem cells and other cells related to development, cancer cells, endothelial cells, and blood-derived inflammatory cells [39, 49–52]. Similarly, GSK-3β has been shown to promote microglial migration both in vitro and in situ [39]. When random and directed migration of BV2 cells were studied using transwell migration and scratch assays, respectively, GSK inhibitors were found to inhibit both types of microglial migration by far more than 50% [39]. The same authors also demonstrated that GSK-3β mediates migration of endogenous mouse microglia in response to slice injury of hippocampus [39]. It is possible that GSK-3β promotes migration/mobility of microglia at least partially by triggering upregulation of CD11b, the αMβ2 integrin and complement receptor, which are needed for adhesion and migration of leukocytes, including microglia [23]. Studies on the role of GSK3 in migration of other cell types support the conclusion that GSK-3β controls multiple pathways involved in migration [28, 30, 51, 53].
4. GSK-3β and Microglial Inflammatory Cytokines, Chemokines and Reactive Oxygen/Nitrogen Species
The production of proinflammatory molecules is a crucial feature of cells needed for innate immune response and the most widely investigated function of microglia in neuroinflammation coupled to AD. Microglia are able to secrete a variety of cytokines and chemokines upon activation by Aβ. These include interleukin 1 (IL-1), interleukin-6 (IL-6), interleukin-8 (IL-8), tumor necrosis factor alpha (TNF-α), as well as chemokines such as macrophage inflammatory protein-1 (MIP-1) and monocyte chemotactic protein-1 (MCP-1) [54]. These secretory products have been postulated to contribute to neuronal death seen in AD brain. In general, cytokines function by regulating the intensity and duration of the immune response [55, 56]. Thus, IL-1 can induce IL-6 production and stimulate synthesis and release of nitric oxide by triggering inducible nitric oxide synthase (iNOS) [57]. This neuroinflammatory stimulation of microglia is further characterized by activation of the complement cascade and induction of the prostanoid generating enzyme cyclooxygenase-2 (COX-2) [57–60]. In addition to this general proinflammatory role, Aβ-induced release of cytokines may promote further Aβ production in microglia. Certain cytokines, such as IL-1, can interact with the amyloid precursor protein (APP) processing pathway resulting in increased cleavage of Aβ [61]. In turn, fibrillar Aβ has been reported to increase neurotoxic secretory products, proinflammatory cytokines and RNS/ROS [5–7]. Eventually, these interactions between cytokines and APP processing establish a self-propagating cycle of neuronal injury [62, 63]. Indeed, several lines of evidence suggest that continuous cytokine production and inflammation-driven cascades cause further activation and recruitment of microglia and can exacerbate disease progression or even sensitize to AD pathology [8, 9]. This continuous reactive microgliosis has been described as the cycle of neuronal death: as in AD brain the cause (Aβ) of microglial activation is not effectively cleared, microglia may enhance their secretion of inflammatory mediators and thus promote toxicity to nearby neurons. However, the causal relationship between microglial activation, cytokine production, Aβ accumulation and neuronal death has not been completely resolved [14].
It is important to note that microglia have also a potential beneficial role in neuroinflammation when another general category of cytokines are released. These antiinflammatory cytokines include IL-1 receptor antagonist (IL-1Ra), IL-4, IL-10, and tumor growth factor beta (TGF-β) [64–68]. IL-4 and TGF-β have a potential to reduce the expression and activity of CD40 and class II MHC [69]. TGFβ has also been reported to reduce Aβ burden in the brain parenchyma in a transgenic mouse model of AD [64]. On the other hand, IL-4 can counteract AD pathology by selectively inducing the clearance of oligomeric Aβ by primary microglia [64, 65]. Similarly, IL-10 can reduce proinflammatory state of microglia by inhibiting the synthesis of cytokines TNFα, IL-1, IL-6, IL-12, granulocyte-macrophage colony stimulating factor (GM-CSF) and chemokines MIP-2, MCP-1 and RANTES [66, 67, 70].
5. Signaling of GSK-3β in Inflammation
GSK-3β is a major regulator of the balance between the above-mentioned proinflammatory and antiinflammatory mediators in immune cells, including microglia [38, 39]. This regulation is manifested by multiple pathways and include interactions with nuclear factor κB (NF-κB) and mixed lineage kinase 3 (MLK3)/c-Jun N-terminal kinase (JNK) signaling pathways [38, 39, 49] (Figure 1).
GSK-3β regulates the production of microglial inflammatory molecules. GSK-3β activation has been shown to increase the production of proinflammatory mediators via multiple mechanisms. GSK-3β is able to activate JNK-, STAT3/5- and NF-κB pathways leading to increased cytokine and chemokine production. GSK-3β is able to increase the binding of coactivator CREB-binding protein (CBP) to p65 thus enhancing NF-κB mediated transcription. Since CREB competes for CBP binding, activation of GSK-3β shifts the balance in favor of NF-κB pathway and CREB-mediated induction of IL-10 is reduced. Moreover, GSK-3β activation leads to proteosomal degradation of beta-catenin, thus resulting in reduced inhibition of NF-κB-activation. All these events lead to enhanced production of proinflammatory molecules.
NF-κB is a dimer protein complex that controls the DNA transcription. In resting microglia, the NF-κB dimers are sequestered in the cytoplasm by inhibitors of κB (IκBs) [71]. Activation of the NF-κB is triggered by the signals that result in degradation of IκB, thereby freeing the NF-κB complex to enter the nucleus and interact with the DNA binding sites of NF-κB [72, 73]. Activation of NF-κB mediates expression of several proinflammatory cytokines and iNOS [74]. Once activated, NF-κB transcriptional activity is further regulated by inducible posttranslational modifications, including phosphorylation and acetylation [49, 75–80]. In certain conditions, GSK-3β may regulate NF-κB activation by phosphorylation of p65 subunit of NF-κB upon TNFα treatment, whereas in cultured microglia LPS treatment induces NF-κB activation by increasing acetylation of p65 at lysine 310 through GSK-3β [49, 75–80]. In fact, several studies support the idea that such acetylation of p65 is required for the full transcriptional activity of NF-κB and that GSK-3β increases the p65 binding of the coactivator CREB-binding protein (CBP), which has acetylase activity. CBP is present in limited amounts and also binds and acetylates transcription factor CREB. Thus, these two transcription factors, the p65 subunit of NF-κB and CREB, compete for CBP and activation of GSK-3β pathway shifts the balance in favor of NF-κB [20, 49, 75–80]. The GSK-3β-mediated increase in NF-κB activity results in expression of proinflammatory cytokines and chemokines, such as TNFα, IL-6 and MCP-1. Simultaneously, the expression of IL-10 is reduced, partially because of the reduced DNA binding activity of CREB and also AP1, which are the main transcription factors contributing to IL-10 expression. The eventual proinflammatory effect of GSK-3β signaling is mediated by reduced IL-10 expression, which leads to further increased synthesis of various cytokines and chemokines [20, 49, 75–80].
β-catenin is a transcriptional coactivator of WNT signaling and a direct target of GSK-3β phosphorylation. β-catenin regulates cell proliferation and inhibits NF-κB [81, 82]. Upon GSK-3β phosphorylation, β-catenin enters the proteasomal degradation pathway resulting in reduced inhibition of NF-κB and thereby increased NF-κB-mediated inflammatory responses [81, 82]. β-catenin expression is increased in microglia of transgenic AD mice and Wnt signaling has been reported to play a role in impaired cognitive functions in transgenic AD mouse models [83, 84].
Activation of IL-6 receptors executes proinflammatory response through activation of STAT3 transcription factor, leading to increased expression of proinflammatory molecules, including IL-6 itself. GSK3β selectively promotes STAT3 and STAT5 activation and thereby IL6-induced proinflammatory responses [38, 49, 85].
Finally, certain proinflammatory responses, such as the LPS-induced activation of microglia involve JNK pathway that is regulated by MLK3. GSK-3β phosphorylation may be needed for proper function and dimerization of MLK3, which eventually leads to increased activity of JNK pathway and TNF-α synthesis [49, 86].
Even though there is substantial evidence for proinflammatory role of GSK-3β in several cell types, including microglial cell lines and primary rodent microglia, there are also studies demonstrating an opposite role for GSK-3β. The contradictory results most likely reflect the dependence on the type of cell, stimulus and experimental conditions as the targets of GSK-3β phosphorylation are numerous and of interacting signaling pathways [87–89].
6. GSK-3β and Phagocytosis
Phagocytosis is a main function of microglia. In vitro microglia have the capacity to phagocytose Aβ, but several studies have failed to show actual Aβ-laden vesicles in microglial cells in animal models of AD or in AD [4, 11, 64]. At least the capacity of successful phagocytosis by microglia is very limited in AD brain and not sufficient to prevent the formation of Aβ plaques [4, 11, 64]. However, modulation of microglial activity may enable microglia to effectively phagocytose Aβ as evidenced by activation of microglia for example by Aβ opsonisation [90, 91]. In models of AD, the pathway resulting in Aβ phagocytosis is initiated when Aβ binds a complex of microglial surface receptors consisting of the α6β1 integrin, CD36, CD47, and the class A scavenger receptor (SRA) [10]. In addition, Toll-like receptors (TLRs) which function as dimers and are often coupled to CD14 coreceptors, functionally interact with other partners of the microglial Aβ binding receptor complex [92–96] and execute phagocytosis associated with increased ROS. In turn, engagement of this receptor complex activates tyrosine kinase-based signaling cascades [10, 97, 98] resulting in beneficial phagocytosis but also in production of reactive oxygen species (ROS) and secretion of cytokines [99, 100].
The role of TLR2 and TLR4 in Aβ phagocytosis and AD is emphasized by numerous studies. The expression of TLR2 and TLR4 receptors are upregulated in both AD brains and in related transgenic mouse models of AD. Also, the microglia associated with Aβ plaques show increased levels of mRNA coding for TLR2, -4, -5, -7, and -9 [101]. In addition, AD mice deficient in TLR4 show increased brain Aβ burden. Stimulation of microglial cells with TLR2 and TLR4 ligands boosts indirect clearance of Aβin vitro [102]. Moreover, induction of monocyte recruitment in response to foreign particles, including Aβ, may require activation of TLR-based signaling pathway. Gene delivery of TLR2-lentivirus into the bone marrow cells can rescue the cognitive decline of TLR2 deficient AD mice [103]. Upon Aβ stimulation, monocytes from normal subjects upregulate TLRs, whereas monocytes from AD patients may fail to do so [104]. Also, the level of TLR4 in monocytic cells of AD patients may be lower compared to levels of TLR4 in the same cell population of healthy controls. Finally, bisdemethoxycurcumin, an antiinflammatory compound, improves the defective clearance of Aβ and the transcription and translation of TLR2-4 in monocytic cells of AD patients [104]. These studies point to the importance of TLR signaling in the phagocytic activity of blood-derived monocytic cells in AD.
Signaling of several TLRs, including TLR2, TLR4, TLR5, and TLR9 is regulated by GSK-3β in human monocytes and is coupled to production of cytokines [39, 41, 105] (Figure 2). Stimulation of TLR receptors activates phosphatidylinositol 3-OH kinase (PI(3)K) pathway activated Akt leading to phosphorylation and inhibition of GSK-3β. As a result, the cells produce less proinflammatory molecules but upregulates production of antiinflammatory cytokines, such as IL-10 [105].
GSK-3β in the regulation of microglial phagocytosis. Microglial phagocytosis has been shown to be enhanced through activation of TLR2/4 pathway. Binding of Aβ to TLR2/4 may result in activation of PI3K signalling eventually leading to inhibition of GSK-3β activation. This in turn shifts the cellular balance towards increase in the production of antiinflammatory cytokines favouring phagocytic microglial phenotype. On the other hand, CD40R-CD40L interaction results in both NF-κB and GSK-3β activation thus increasing proinflammatory cytokine production. This may shift the phenotype of microglial cells being less capable of clearing Aβ.
Another pathway relevant for Aβ clearance is triggered by activation of CD40R, a transmembrane receptor of the TNF gene superfamily that is expressed on a variety of cells, such as monocytes, B-cells, antigen presenting cells, endothelial, smooth muscle cells, fibroblasts, and microglia [50]. CD40L is an immunoregulatory molecule that is expressed by activated T-cells, for example. By preventing the CD40-CD40L interaction in AD transgenic mice [106, 107] the Aβ burden is reduced. Aβ stimulation in the presence of CD40-CD40L interaction has been demonstrated to cause diminished microglial phagocytosis and a shift in balance towards an adaptive, antigen-presenting state [108]. It is conceivable that CD40R is activated in microglial cells in AD. The interaction between CD40 and CD40L enhances the expression of cytokines, chemokines, matrix metalloproteinases, growth factors, and adhesion molecules, mainly through the stimulation of NF-κB and also by GSK-3β, which has a role in CD40-mediated response and polarization of naïve CD4+ T cells to Th2 cells [50, 51].
7. Concluding Remarks
Inflammation and especially microglial activation is a contributory factor in neurodegeneration, including AD. Without question, GSK-3β is a central mediator molecule of harmful inflammatory mechanisms relevant to AD. Several studies convincingly link the role of tau and Aβ to increased activity of GSK-3β in the brain [109–114]. Indeed, both human and rodent model studies on AD indicate that inhibition of GSK-3β can be expected to be beneficial in AD [115–120]. Even though some small molecules inhibiting GSK-3β reduce memory/learning deficits and also inflammation in transgenic mouse models of AD [115–120], the link between GSK-3β and harmful inflammation in AD has not been much explored. There are hardly any investigations on the Aβ or tau-related harmful inflammation through mechanisms involving GSK-3β. Based on the overall literature on inflammation, microglia, and AD, we hypothesize that GSK-3β is a potential therapeutic target uniting Aβ deposition, tau aggregation, and inflammation, which represent all the key components of AD pathology.
Acknowledgments
The authors thank The Academy of Finland and The Sigrid Juselius Foundation for their support.
HardyJ. A.HigginsG. A.Alzheimer's disease: the amyloid cascade hypothesis199225650541841852-s2.0-0026597063CrouchP. J.HardingS. M. E.WhiteA. R.CamakarisJ.BushA. I.MastersC. L.Mechanisms of Aβ mediated neurodegeneration in Alzheimer's disease20084021811982-s2.0-3624895712210.1016/j.biocel.2007.07.013MichelucciA.HeurtauxT.GrandbarbeL.MorgaE.HeuschlingP.Characterization of the microglial phenotype under specific pro-inflammatory and anti-inflammatory conditions: effects of oligomeric and fibrillar amyloid-β20092101-23122-s2.0-6734925147910.1016/j.jneuroim.2009.02.003HenekaM. T.O'BanionM. K.TerwelD.KummerM. P.Neuroinflammatory processes in Alzheimer's disease201011789199472-s2.0-7795441929710.1007/s00702-010-0438-zEikelenboomP.Van GoolW. A.Neuroinflammatory perspectives on the two faces of Al'zheimer's disease200411132812942-s2.0-154228361110.1007/s00702-003-0055-1EikelenboomP.ZhanS. S.Van GoolW. A.AllsopD.Inflammatory mechanisms in Alzheimer's disease199415124474502-s2.0-002809962210.1016/0165-6147(94)90057-4McGeerP. L.McGeerE. G.The inflammatory response system of brain: implications for therapy of Alzheimer and other neurodegenerative diseases19952121952182-s2.0-002961001110.1016/0165-0173(95)00011-9AkiyamaH.BargerS.BarnumS.BradtB.BauerJ.ColeG. M.CooperN. R.EikelenboomP.EmmerlingM.FiebichB. L.FinchC. E.FrautschyS.GriffinW. S. T.HampelH.HullM.LandrethG.LueL. F.MrakR.MacKenzieI. R.McGeerP. L.O'BanionM. K.PachterJ.PasinettiG.Plata-SalamanC.RogersJ.RydelR.ShenY.StreitW.StrohmeyerR.TooyomaI.Van MuiswinkelF. L.VeerhuisR.WalkerD.WebsterS.WegrzyniakB.WenkG.Wyss-CorayT.Inflammation and Alzheimer's disease20002133834212-s2.0-003461217510.1016/S0197-4580(00)00124-XMcGeerP. L.McGeerE. G.Inflammation, autotoxicity and Alzheimer disease20012267998092-s2.0-003569392410.1016/S0197-4580(01)00289-5BambergerM. E.HarrisM. E.McDonaldD. R.HusemannJ.LandrethG. E.A cell surface receptor complex for fibrillar β-amyloid mediates microglial activation2003237266526742-s2.0-0037387147MalmT. M.KoistinahoM.PärepaloM.VatanenT.OokaA.KarlssonS.KoistinahoJ.Bone-marrow-derived cells contribute to the recruitment of microglial cells in response to β-amyloid deposition in APP/PS1 double transgenic Alzheimer mice20051811341422-s2.0-1184425577910.1016/j.nbd.2004.09.009RansohoffR. M.Chemokines and chemokine receptors: standing at the crossroads of immunobiology and neurobiology20093157117212-s2.0-7044952570410.1016/j.immuni.2009.09.010HanischU. K.KettenmannH.Microglia: active sensor and versatile effector cells in the normal and pathologic brain20071011138713942-s2.0-3554898630410.1038/nn1997HanischU. K.Microglia as a source and target of cytokines20024021401552-s2.0-003684901810.1002/glia.10161GorlovoyP.LarionovS.PhamT. T. H.NeumannH.Accumulation of tau induced in neurites by microglial proinflammatory mediators2009238250225132-s2.0-6884912307910.1096/fj.08-123877KoistinahoM.KoistinahoJ.Role of p38 and p44/42 mitogen-activated protein kinases in microglia20024021751832-s2.0-003684784010.1002/glia.10151KoistinahoM.KoistinahoJ.Interactions between Alzheimer's disease and cerebral ischemia - Focus on inflammation20054822402502-s2.0-1784438579110.1016/j.brainresrev.2004.12.014LueL. F.YanS. D.SternD. M.WalkerD. G.Preventing activation of receptor for advanced glycation endproducts in Alzheimer's disease2005432492662-s2.0-1994442414210.2174/1568007054038210BeurelE.JopeR. S.Glycogen synthase kinase-3 regulates inflammatory tolerance in astrocytes2010693106310702-s2.0-7795348842410.1016/j.neuroscience.2010.05.044BeurelE.MichalekS. M.JopeR. S.Innate and adaptive immune responses regulated by glycogen synthase kinase-3 (GSK3)201031124312-s2.0-7314909723410.1016/j.it.2009.09.007WoodgettJ. R.Molecular cloning and expression of glycogen synthase kinase-3/factor A199098243124382-s2.0-0025286104MukaiF.IshiguroK.SanoY.FujitaS. C.Aternative splicing isoform of tau protein kinase I/glycogen synthase kinase 3β2002815107310832-s2.0-003598353310.1046/j.1471-4159.2002.00918.xSolovjovD. A.PluskotaE.PlowE. F.Distinct roles for the α and β subunits in the functions of integrin αβ20052802133613452-s2.0-1254425299610.1074/jbc.M406968200SchafferB.Wiedau-PazosM.GeschwindD. H.Gene structure and alternative splicing of glycogen synthase kinase 3 beta (GSK-3β) in neural and non-neural tissues20033021-273812-s2.0-003741369410.1016/S0378-1119(02)01092-2Wood-KaczmarA.KrausM.IshiguroK.PhilpottK. L.Gordon-WeeksP. R.An alternatively spliced form of glycogen synthase kinase-3β is targeted to growing neurites and growth cones20094231841942-s2.0-6934908788810.1016/j.mcn.2009.07.002HurE.-M.ZhouF.-Q.fzhou4@jhmi.eduGSK3 signalling in neural development201011853955110.1038/nrn2870CastañoZ.Gordon-WeeksP. R.KyptaR. M.The neuron-specific isoform of glycogen synthase kinase-3β is required for axon growth201011311171302-s2.0-7774924306510.1111/j.1471-4159.2010.06581.xOwenR.Gordon-WeeksP. R.Inhibition of glycogen synthase kinase 3β in sensory neurons in culture alters filopodia dynamics and microtubule distribution in growth cones20032346266372-s2.0-004266121210.1016/S1044-7431(03)00095-2YoshimuraT.KawanoY.ArimuraN.KawabataS.KikuchiA.KaibuchiK.GSK-3β regulates phosphorylation of CRMP-2 and neuronal polarity200512011371492-s2.0-1184429777110.1016/j.cell.2004.11.012FarooquiR.ZhuS.FenteanyG.Glycogen synthase kinase-3 acts upstream of ADP-ribosylation factor 6 and Rac1 to regulate epithelial cell migration20063129151415252-s2.0-3364615772710.1016/j.yexcr.2006.01.018KimW. Y.WangX.WuY.DobleB. W.PatelS.WoodgettJ. R.SniderW. D.GSK-3 is a master regulator of neural progenitor homeostasis20091211139013972-s2.0-74949109403BultjeR. S.Castaneda-CastellanosD. R.JanL. Y.JanY. N.KriegsteinA. R.ShiS. H.Mammalian par3 regulates progenitor cell asymmetric division via notch signaling in the developing neocortex20096321892022-s2.0-6765089823810.1016/j.neuron.2009.07.004KwokJ. B. J.HalluppM.LoyC. T.ChanD. K. Y.WooJ.MellickG. D.BuchananD. D.SilburnP. A.HallidayG. M.SchofieldP. R.GSK3B polymorphisms alter transcription and splicing in Parkinson's disease20055868298392-s2.0-2854443524010.1002/ana.20691KwokJ. B. J.LoyC. T.HamiltonG.LauE.HalluppM.WilliamsJ.OwenM. J.BroeG. A.TangN.LamL.PowellJ. F.LovestoneS.SchofieldP. R.Glycogen synthase kinase-3β and tau genes interact in Alzheimer's disease20086444464542-s2.0-5584909065110.1002/ana.21476ShinJ.YuS.-B.YuU. Y.JoS. A.AhnJ.-H.ahnj@ewha.ac.krSwedish mutation within amyloid precursor protein modulates global gene expression towards the pathogenesis of Alzheimer's disease2010431070470910.3858/BMBRep.2010.43.10.704AvilaJ.WandosellF.HernándezF.Role of glycogen synthase kinase-3 in Alzheimer's disease pathogenesis and glycogen synthase kinase-3 inhibitors20101057037102-s2.0-7795187590210.1586/ern.10.40MaoY.GeX.FrankC. L.MadisonJ. M.KoehlerA. N.DoudM. K.TassaC.BerryE. M.SodaT.SinghK. K.BiecheleT.PetryshenT. L.MoonR. T.HaggartyS. J.TsaiLI. H.Disrupted in schizophrenia 1 regulates neuronal progenitor proliferation via modulation of GSK3β/β-Catenin Signaling20091366101710312-s2.0-6214908380610.1016/j.cell.2008.12.044BeurelE.JopeR. S.Lipopolysaccharide-induced interleukin-6 production is controlled by glycogen synthase kinase-3 and STAT3 in the brain20096, article 92-s2.0-6354915115410.1186/1742-2094-6-9YuskaitisC. J.JopeR. S.Glycogen synthase kinase-3 regulates microglial migration, inflammation, and inflammation-induced neurotoxicity20092122642732-s2.0-5774917384410.1016/j.cellsig.2008.10.014DingY.QiaoA.FanG. H.Indirubin-3'-monoxime rescues spatial memory deficits and attenuates β-amyloid-associated neuropathology in a mouse model of Alzheimer's disease20103921561682-s2.0-7795371822010.1016/j.nbd.2010.03.022HuangW. C.LinY. S.WangC. Y.TsaiC. C.TsengH. C.ChenC. L.LuP. J.ChenPO. S.QianLI.HongJ. S.LinC. F.Glycogen synthase kinase-3 negatively regulates anti-inflammatory interleukin-10 for lipopolysaccharide-induced iNOS/NO biosynthesis and RANTES production in microglial cells20091281, supplemente275e2862-s2.0-6824915958410.1111/j.1365-2567.2008.02959.xMalmT.KoistinahoM.MuonaA.MaggaJ.KoistinahoJ.The role and therapeutic potential of monocytic cells in Alzheimer's disease20105888899002-s2.0-7795256897510.1002/glia.20973ChoiJ.ZhengQ.KatzH. E.GuilarteT. R.Silica-based nanoparticle uptake and cellular response by primary microglia201011855895952-s2.0-7795171009410.1289/ehp.0901534Reed-GeaghanE. G.SavageJ. C.HiseA. G.LandrethG. E.CD14 and toll-like receptors 2 and 4 are required for fibrillar Aβ-stimulated microglial activation2009293811982119922-s2.0-7034932341710.1523/JNEUROSCI.3158-09.2009Koronyo-HamaouiM.KoM. K.KoronyoY.AzoulayD.SeksenyanA.KunisG.PhamM.BakhsheshianJ.RogeriP.BlackK. L.FarkasD. L.SchwartzM.Attenuation of AD-like neuropathology by harnessing peripheral immune cells: local elevation of IL-10 and MMP-920091116140914242-s2.0-7045021533210.1111/j.1471-4159.2009.06402.xYamamotoM.KiyotaT.WalshS. M.LiuJ.KipnisJ.IkezuT.Cytokine-mediated inhibition of fibrillar amyloid-β peptide degradation by human mononuclear phagocytes20081816387738862-s2.0-56149091817TeixeiraA. L.ReisH. J.CoelhoF. M.CarneiroD. S.TeixeiraM. M.VieiraL. B.MukhamedyarovM. A.ZefirovA. L.JankaZ.PalotásA.palotas@asklepios-med.euAll-or-nothing type biphasic cytokine production of human lymphocytes after exposure to Alzheimer's β-Amyloid peptide2008641089189510.1016/j.biopsych.2008.07.019RealeM.IarloriC.FelicianiC.GambiD.Peripheral chemokine receptors, their ligands, cytokines and Alzheimer's disease20081421471592-s2.0-47849132772WangM.-J.mjwang@tzuchi.com.twHuangH.-Y.93351113@stmail.tcu.edu.twChenW.-F.wfchen@ms29.hinet.netChangH.-F.check172@yahoo.com.twKuoJ.-S.jskuo@mail.tcu.edu.twGlycogen synthase kinase-3β inactivation inhibits tumor necrosis factor-α production in microglia by modulating nuclear factor κB and MLK3/JNK signaling cascades20103119910.1186/1742-2094-7-99ChatzigeorgiouA.LyberiM.ChatzilymperisG.NezosA.KamperE.CD40/CD40L signaling and its implication in health and disease20093564744832-s2.0-7334910946410.1002/biof.62OnoT.YanagawaY.IwabuchiK.NonomuraK.OnoéK.Glycogen synthase kinase 3 activity during development of bone marrow-derived dendritic cells (DCs) essential for the DC function to induce T helper 2 polarization200712221891982-s2.0-3454859704510.1111/j.1365-2567.2007.02627.xLiQ.MichaudM.CanosaS.KuoA.MadriJ. A.GSK-3β: a signaling pathway node modulating neural stem cell and endothelial cell interactionsAngiogenesis, 2011, In pressNeumannH.hneuman1@uni-bonn.deLinnartzB.linnartz@uni-bonn.deWangY.yinerwang@uni-bonn.deMicroglial immunoreceptor tyrosine-based activation and inhibition motif signaling in neuroinflammation20102010758746310.4061/2010/587463RogersJ.LueL. F.Microglial chemotaxis, activation, and phagocytosis of amyloid β-peptide as linked phenomena in Alzheimer's disease2001395-63333402-s2.0-003481405610.1016/S0197-0186(01)00040-7TuppoE. E.AriasH. R.The role of inflammation in Alzheimer's disease20053722893052-s2.0-494425871610.1016/j.biocel.2004.07.009HenekaM. T.O'BanionM. K.Inflammatory processes in Alzheimer's disease20071841-269912-s2.0-3384761388510.1016/j.jneuroim.2006.11.017AbbasN.BednarI.MixE.MarieS.PatersonD.LjungbergA.MorrisC.WinbladB.NordbergA.ZhuJ.Up-regulation of the inflammatory cytokines IFN-γ and IL-12 and down-regulation of IL-4 in cerebral cortex regions of APP transgenic mice20021261-250572-s2.0-2024436422610.1016/S0165-5728(02)00050-4BezziP.DomercqM.BrambillaL.GalliR.ScholsD.De ClercqE.VescoviA.BagettaG.KolliasG.MeldolesiJ.VolterraA.CXCR4-activated astrocyte glutamate release via TNFa: amplification by microglia triggers neurotoxicity2001477027102-s2.0-003496022810.1038/89490BezziP.DomercqM.VesceS.VolterraA.Neuron-astrocyte cross-talk during synaptic transmission: physiological and neuropathological implications20011322552652-s2.0-003578399110.1016/S0079-6123(01)32081-2BrownG. C.Bal-PriceA.Inflammatory neurodegeneration mediated by nitric oxide, glutamate, and mitochondria20032733253552-s2.0-004178469810.1385/MN:27:3:325BlaskoI.MarxF.SteinerE.HartmannT.Grubeck-LoebensteinB.Beatrix.Grubeck@oeaw.ac.atTNFα plus IFNγ induce the production of alzheimer β-amyloid peptides and decrease the secretion of APPs19991316368GriffinW. S. T.IL-1 and the cytokine cycle in Alzheimer’s disease200074S52MrakR. E.GriffinW. S. T.Interleukin-1, neuroinflammation, and Alzheimer's disease20012269039082-s2.0-003569097610.1016/S0197-4580(01)00287-1Wyss-CorayT.LinC.YanF.YuG. Q.RohdeM.McconlogueL.MasliahE.MuckeL.TGF-β1 promotes microglial amyloid-β clearance and reduces plaque burden in transgenic mice2001756126182-s2.0-003474429610.1038/87945KiyotaT.OkuyamaS.SwanR. J.JacobsenM. T.GendelmanH. E.IkezuT.tikezu@unmc.eduCNS expression of anti-inflammatory cytokine interleukin-4 attenuates Alzheimer's disease-like pathogenesis in APP+PS1 bigenic mice20102483093310210.1096/fj.10-155317HuS.ChaoC. C.EhrlichL. C.ShengW. S.SuttonR. L.RockswoldG. L.PetersonP. K.Inhibition of microglial cell RANTES production by IL-10 and TGF-β19996568158212-s2.0-0033039422MooreK. W.De Waal MalefytR.CoffmanR. L.O'GarraA.Interleukin-10 and the interleukin-10 receptor2001196837652-s2.0-003506202110.1146/annurev.immunol.19.1.683ShimizuE.KawaharaK.KajizonoM.SawadaM.NakayamaH.IL-4-induced selective clearance of oligomeric β-amyloid peptide(1–42) by rat primary type 2 microglia20081819650365132-s2.0-58749093072BenvenisteE. N.NguyenV. T.O'KeefeG. M.Immunological aspects of microglia: relevance to Alzheimer's disease2001395-63813912-s2.0-003480257010.1016/S0197-0186(01)00045-6HaoJ.WangZ. D.YangY. X.Study on β-amyloid peptide 1–42 induced chemokine rantes in U251 cell2009406101110142-s2.0-73049087807DidonatoJ. A.HayakawaM.RothwarfD. M.ZandiE.KarinM.karin_office@som-BSB.ucsd.eduA cytokine-responsive IκB kinase that activates the transcription factor NF-κB1997388664254855410.1038/41493KarinM.Ben-NeriahY.Phosphorylation meets ubiquitination: the control of NF-[kappa]B activity200018621663HanadaT.YoshimuraA.yakihiko@bioreg.kyushu-u.ac.jpRegulation of cytokine signaling and inflammation2002134-541342110.1016/S1359-6101(02)00026-6MorrisK. R.LutzR. D.ChoiH. S.KamitaniT.ChmuraK.ChanE. D.Role of the NF-κB signaling pathway and κB cis-regulatory elements on the IRF-1 and iNOS promoter regions in mycobacterial lipoarabinomannan induction of nitric oxide2003713144214522-s2.0-003733258910.1128/IAI.71.3.1442-1452.2003VermeulenL.De WildeG.NotebaertS.Vanden BergheW.HaegemanG.Regulation of the transcriptional activity of the nuclear factor-κB p65 subunit2002645-69639702-s2.0-003671047910.1016/S0006-2952(02)01161-9HaydenM. S.GhoshS.Signaling to NF-κB20041818219522242-s2.0-444437671210.1101/gad.1228704SchmitzM. L.MattioliI.BussH.KrachtM.NF-κB: a multifaceted transcription factor regulated at several levels2004510134813582-s2.0-564423548810.1002/cbic.200400144GongR.RifaiA.GeY.ChenS.DworkinL. D.Hepatocyte growth factor suppresses proinflammatory NFκB activation through GSK3β inactivation in renal tubular epithelial cells200828312740174102-s2.0-4314912272510.1074/jbc.M710396200ChenL. F.MuY.GreeneW. C.Acetylation of RelA at discrete sites regulates distinct nuclear functions of NF-κB20022123653965482-s2.0-003701105610.1093/emboj/cdf660KiernanR.BrèsV.NgR. W. M.CoudartM. P.El MessaoudiS.SardetC.JinD. Y.EmilianiS.BenkiraneM.Post-activation turn-off of NF-κB-dependent transcription is regulated by acetylation of p6520032784275827662-s2.0-003746272510.1074/jbc.M209572200Coyle-RinkJ.Del ValleL.SweetT.KhaliliK.AminiS.Developmental expression of Wnt signaling factors in mouse brain2002166406452-s2.0-0038650954DuanY.LiaoA. P.KuppireddiS.YeZ.CiancioM. J.SunJ.β-Catenin activity negatively regulates bacteria-induced inflammation20078766136242-s2.0-3424903492510.1038/labinvest.3700545LiH. L.WangH. H.LiuS. J.Phosphorylation of tau antagonizes apoptosis by stabilizing beta-catenin, a mechanism involved in Alzheimer's neurodegeneration2007104935913596HalleskogC.MulderJ.DahlströmJ.MackieK.HortobágyiT.TanilaH.Kumar PuliL.FärberK.HarkanyT.SchulteG.gunnar.schulte@ki.seWNT signaling in activated microglia is proinflammatory201159111913110.1002/glia.21081TakadaY.FangX.JamaluddinM. S.BoydD. D.AggarwalB. B.Genetic deletion of glycogen synthase kinase-3β abrogates activation of IκBα kinase, JNK, Akt, and p44/p42 MAPK but potentiates apoptosis induced by tumor necrosis factor20042793839541395542-s2.0-454434111610.1074/jbc.M403449200LeungI. W. L.LassamN.Dimerization via tandem leucine zippers is essential for the activation of the mitogen-activated protein kinase kinase kinase, MLK-319982734932408324152-s2.0-003248421510.1074/jbc.273.49.32408ShenF.ZhaoM. W.HeB.YangJ. J.PeiF.WangY. Z.The changes and significance of interleukin-17 in rat models of chronic obstructive pulmonary disease and asthma20042710654658ShenE.FanJ.PengT.Glycogen synthase kinase-3beta suppresses tumor necrosis factor-alpha expression in cardiomyocytes during lipopolysaccharide stimulation200810413293382-s2.0-4644910740210.1002/jcb.21629VinesA.CahoonS.GoldbergI.SaxenaU.PillarisettiS.Novel anti-inflammatory role for glycogen synthase kinase-3β in the inhibition of tumor necrosis factor-α- and interleukin-1β-induced inflammatory gene expression20062812516985169902-s2.0-3374520991810.1074/jbc.M602446200BardF.CannonC.BarbourR.tpeng2@uwo.caPeripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease200068916919SchenkD.BarbourR.DunnW.GordonG.GrajedaH.GuldoT.HuK.HuangJ.Johnson-WoodK.KhanK.KholodenkoD.LeeM.LiaoZ.LieberburgI.MotterR.MutterL.SorianoF.ShoppG.VasquezN.VandevertC.WalkerS.WogulisM.YednockT.GamesD.SeubertP.Immunization with amyloid-β attenuates Alzheimer disease-like pathology in the PDAPP mouse199940067401731772-s2.0-003353616310.1038/22124Reed-GeaghanE. G.SavageJ. C.HiseA. G.LandrethG. E.CD14 and toll-like receptors 2 and 4 are required for fibrillar Aβ-stimulated microglial activation2009293811982119922-s2.0-7034932341710.1523/JNEUROSCI.3158-09.2009KielianT.Toll-like receptors in central nervous system glial inflammation and homeostasis20068357117302-s2.0-3364532293810.1002/jnr.20767PfeifferA.BöttcherA.OrsóE.KapinskyM.NagyP.BodnrA.SpreitzerI.LiebischG.DrobnikW.GempelK.HornM.HolmerS.HartungT.MulthoffG.SchtzG.SchindlerH.UlmerA. J.HeineH.StelterF.SchttC.RotheG.SzlliJ.DamjanovichS.SchmitzG.Lipopolysaccharide and ceramide docking to CD14 provokes ligand-specific receptor clustering in rafts20013111315331642-s2.0-003519176910.1002/1521-4141(200111)31:11<3153::AID-IMMU3153>3.0.CO;2-0TriantafilouM.GamperF. G. J.HastonR. M.MouratisM. A.MorathS.HartungT.TriantafilouK.Membrane sorting of toll-like receptor (TLR)-2/6 and TLR2/1 heterodimers at the cell surface determines heterotypic associations with CD36 and intracellular targeting20062814131002310112-s2.0-3375007063110.1074/jbc.M602794200TriantafilouM.MorathS.MackieA.HartungT.TriantafilouK.Lateral diffusion of Toll-like receptors reveals that they are transiently confined within lipid rafts on the plasma membrane200411717400740142-s2.0-444426484210.1242/jcs.01270McDonaldD. R.BrundenK. R.LandrethG. E.Amyloid fibrils activate tyrosine kinase-dependent signaling and superoxide production in microglia1997177228422942-s2.0-0030961544CombsC. K.JohnsonD. E.CannadyS. B.LehmanT. M.LandrethG. E.Identification of microglial signal transduction pathways mediating a neurotoxic response to amyloidogenic fragments of β-amyloid and prion proteins19991939289392-s2.0-0033080919KoenigsknechtJ.LandrethG.Microglial phagocytosis of fibrillar β-amyloid through a β integrin-dependent mechanism20042444983898462-s2.0-774423586910.1523/JNEUROSCI.2557-04.2004WilkinsonB.Koenigsknecht-TalbooJ.GrommesC.LeeC. Y.LandrethG.Fibrillar beta-amyloid-stimulated intracellular signaling cascades require Vav for induction of respiratory burst and phagocytosis in monocytes and microglia2006281302084220850FrankS.CopanakiE.BurbachG. J.MüllerU. C.DellerT.Differential regulation of toll-like receptor mRNAs in amyloid plaque-associated brain tissue of aged APP23 transgenic mice2009453141442-s2.0-6094910881210.1016/j.neulet.2009.01.075TaharaK.KimH. D.JinJ. J.MaxwellJ. A.LiL.FukuchiK.Role of toll-like receptor signalling in Abeta uptake and clearance20061291130063019RichardK. L.FilaliM.PréfontaineP.RivestS.Toll-like receptor 2 acts as a natural innate immune receptor to clear amyloid β and delay the cognitive decline in a mouse model of Alzheimer's disease20082822578457932-s2.0-4594910607710.1523/JNEUROSCI.1146-08.2008FialaM.LiuP. T.Espinosa-JeffreyA.RosenthalM. J.BernardG.RingmanJ. M.SayreJ.ZhangL.ZaghiJ.DejbakhshS.ChiangB.HuiJ.MahanianM.BaghaeeA.HongP.CashmanJ.Innate immunity and transcription of MGAT-III and Toll-like receptors in Alzheimer's disease patients are improved by bisdemethoxycurcumin20071043112849128542-s2.0-3454788911410.1073/pnas.0701267104MartinM.RehaniK.JopeR. S.MichalekS. M.Toll-like receptor—mediated cytokine production is differentially regulated by glycogen synthase kinase 32005687777842-s2.0-2394448675010.1038/ni1221TanJ.TownT.CrawfordF.MoriT.DelleDonneA.CrescentiniR.ObregonD.FlavelR. A.MullanM. J.mmullan@hsc.usf.eduRole of CD40 ligand in amyloidosis in transgenic Alzheimer's mice20025121288129310.1038/nn968LaporteV.LombardY.Levy-BenezraR.TranchantC.PoindronP.poindron@pharma.u-strasbg.frWarterJ. -M.Uptake of Aβ 1–40- and Aβ 1–42-coated yeast by microglial cells: a role for LRP200476245146110.1189/jlb.1203620TownT.terrence.town@yale.eduNikolicV.vnikolic@smtp.hsc.usf.eduTanJ.jtan@hsc.usf.eduThe microglial “activation” continuum: from innate to adaptive responses20052, article 2410.1186/1742-2094-2-24TerwelD.MuyllaertD.DewachterI.BorghgraefP.CroesS.DevijverH.Van LeuvenF.Amyloid activates GSK-3β to aggravate neuronal tauopathy in bigenic mice200817237867982-s2.0-4044909895210.2353/ajpath.2008.070904MuyllaertD.KremerA.JaworskiT.BorghgraefP.DevijverH.CroesS.DewachterI.Van LeuvenF.fredvl@med.kuleuven.beGlycogen synthase kinase-3β, or a link between amyloid and tau pathology?20087supplement 1576610.1111/j.1601-183X.2007.00376.xLiH. L.WangH. H.LiuS. J.Phosphorylation of tau antagonizes apoptosis by stabilizing beta-catenin, a mechanism involved in Alzheimer's neurodegeneration2007104935913596LeroyK.YilmazZ.BrionJ. P.Increased level of active GSK-3β in Alzheimer's disease and accumulation in argyrophilic grains and in neurones at different stages of neurofibrillary degeneration200733143552-s2.0-3384612943410.1111/j.1365-2990.2006.00795.xTakashimaA.kenneth@brain.riken.go.jpGSK-3 is essential in the pathogenesis of Alzheimer's disease20069supplement 3309317MateoI.InfanteJ.LlorcaJ.RodríguezE.BercianoJ.CombarrosO.combarro@unican.esAssociation between glycogen synthase kinase-3β genetic polymorphism and late-onset Alzheimer's disease200621422823210.1159/000091044BustanjiY.bustanji@ju.edu.joTahaM. O.AlmasriI. M.Al-GhusseinM. A. S.MohammadM. K.AlkhatibH. S.Inhibition of glycogen synthase kinase by curcumin: Investigation by simulated molecular docking and subsequent in vitro/in vivo evaluation200924377177810.1080/14756360802364377LimG. P.ChuT.YangF.BeechW.FrautschyS. A.ColeG. M.gmcole@ucla.eduThe curry spice curcumin reduces oxidative damage and amyloid pathology in an Alzheimer transgenic mouse2001212183708377LimG. P.YangF.ChuT.ChenP.BeechW.TeterB.TranT.UbedaO.AsheK. H.FrautschyS. A.ColeG. M.gmcole@ucla.eduIbuprofen suppresses plaque pathology and inflammation in a mouse model for Alzheimer's disease2000201557095714GreenspanE. J.MadiganJ. P.BoardmanL. A.RosenbergD. W.rosenberg@uchc.eduIbuprofen inhibits activation of nuclear β-catenin in human colon adenomas and induces the phosphorylation of GSK-3β20114116117110.1158/1940-6207.CAPR-10-0021MalmT. M.IivonenH.GoldsteinsG.Keksa-GoldsteineV.AhtoniemiT.KanninenK.SalminenA.AuriolaS.Van GroenT.TanilaH.KoistinahoJ.jari.koistinaho@uku.fiPyrrolidine dithiocarbamate activates Akt and improves spatial learning in APP/PS1 mice without affecting β-amyloid burden200727143712372110.1523/JNEUROSCI.0059-07.2007NurmiA.GoldsteinsG.NärväinenJ.PihlajaR.AhtoniemiT.GröhnO.KoistinahoJ.Jari.Koistinaho@uku.fiAntioxidant pyrrolidine dithiocarbamate activates Akt-GSK signaling and is neuroprotective in neonatal hypoxia-ischemia200640101776178410.1016/j.freeradbiomed.2006.01.011